Breaking News
Get 50% Off 0
📌 New AI-picked stocks coming soon. 3 picks from last month are already up +30%...
Get early access
Close

CervoMed Inc (CRVO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow CervoMed's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
8.4200 -0.2500    -2.88%
29/07 - Closed. Currency in USD
After Hours
8.1600
-0.2600
-3.0879%
0:50:33 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 603,482
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 8.2700 - 9.4199
CervoMed 8.4200 -0.2500 -2.88%

CervoMed Inc Company Profile

 
Get an in-depth profile of CervoMed Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

15

Equity Type

ORD

CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurological disorders. It is being evaluated in a Phase 2b study in patients with DLB. The company develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

Contact Information

Address 20 Park Plaza Suite 424
Boston, 02116
United States
Phone 617 744 4400
Fax -

Top Executives

Name Age Since Title
John J. Alam 62 2023 Co-Founder, CEO, President & Director
Joshua S. Boger 73 2024 Independent Chair of the Board
Sylvie L. Gregoire 64 2023 Co-Founder & Director
Ole Isacson 64 - Chair of the Scientific Advisory Board
Marwan Noel Sabbagh 59 2023 Independent Non-Executive Director
Jeffrey V. Poulton 57 2023 Independent Director
Jeffrey L. Cummings 75 - Member Scientific of Advisory Board
Heidi McBride - - Member of Scientific Advisory Board
Lewis clayton Cantley 76 - Member of Scientific Advisory Board
Frank E. Zavrl 59 2023 Independent Director
Jane Holmes Hollingsworth 66 2020 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

CRVO Comments

Write your thoughts about CervoMed Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email